Klin Farmakol Farm. 2011;25(1):33-34
New drug in the symptomatic treatment of multiple sclerosis: 4-aminopyridin (FAMPRIDINE - SR)
- Neurologická klinika FN a MU v Brně
FAMPRIDINE – SR, a sustained – release formulation of fampridine (4-aminopyridine), is a potassium channel blocker in central nervous system
acting on internodal membrane of demyelinated axons thus improving conduction of electrical impulse. FAMPRIDINE – SR is administered
perorally twice daily in single dose of 10 milligrams. FAMPRIDINE – SR demonstrated improvement of walking ability in some patients with
multiple sclerosis. The improvement is statistically significant and has a clinical meaningful therapeutic benefit.
Keywords: 4-aminopyridine, FAMPRIDINE – SR, multiple sclerosis
Published: March 18, 2011 Show citation
References
- Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58(6): 961-967.
Go to original source... 
Go to PubMed... - Goodman AD, Brown TR, Krupp LB, Schapiro RT, Swid SR, Cohen R, Marinucci LN, Blight AR. Sustained - release oral fampridine in multiple sclerosis: a randomised, double - blind, controlled trial. Lancet 2009; 373: 732-738. Go to original source... Go to PubMed...
- Hayes KC, Katz MA, Devane JG, Hsieh JT, Wolfe DL, Potter PJ, Blight AR. Pharmacokinetics of an immediate - release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patiens with spinal cord injury. J Clin Pharmacol 2003; 42: 379-385. Go to original source... Go to PubMed...
- Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained - release 4 - aminopyridine (Fampridine - SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004; 85: 29-34. Go to original source... Go to PubMed...
- Kaufman M, Moyer D, Norton J. The significant change for the Timed 25 - Foot Walk in the Multiple Sclerosis Functional Composite. Mult Scler 2000; 4: 286-290. Go to original source... Go to PubMed...
- Koch M, Uyttenboogaart M, Polman S, De Keyser J. Seizures in multiple sclerosis. Epilepsia 2008; 49: 948-953. Go to original source... Go to PubMed...
- Ozakbas S, Cagiran I, Ormeci B, Idiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health related quality of life during and after treatment of relapses in patiens with multiple sclerosis. J Neurol Sci 2004; 218: 3-7. Go to original source... Go to PubMed...
- Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4 - amidopyridine in multiple sclerosis: prolonged administration. Neurology 1991; 41: 1344-1348. Go to original source... Go to PubMed...
- Targ EF, Kocsis JD. 4 - Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res. 1985; 328(2): 358-361. Go to original source... Go to PubMed...
- van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double - blind, cross-over study. Ann Neurol 1992; 32: 123-130. Go to original source... Go to PubMed...